The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects

Journal of Clinical Psychopharmacology

Volumn 17, Issue 1, 1997, Pages 27-33

  Marino, Maria R ^a   Langenbacher, Kathleen M ^a   Hammett, Janis L ^a   Nichola, Peter ^a   Uderman, Howard D ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b University Medical Center at Princeton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEFAZODONE; PHENYTOIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; MALE; METABOLIC CLEARANCE RATE; PHENYTOIN; TRIAZOLES;

EID: 0031030906     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199702000-00006     Document Type: Article

References (30)

1. Rickels K, Schweizer E, Clary C, Fox I, Weice C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-5.
2. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-41.
3. Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995;56:30-6.
4. Bristol-Myers Squibb Company. Nefazodone HCl prescribing information. Princeton, NJ, 1995.
5. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-5.
6. Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995;35:830-9.
7. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Dextromethorphan O-, N-demethylation in vitro. Inhibition by nefazodone and its metabolites [abstract]. J Clin Pharmacol 1995;35:925.
8. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II: A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-6.
9. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacology 1995;15:399-408.
10. Garnett WR. Epilepsy. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke G, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 2nd ed. Norwalk, CT: Appleton & Lange, 1993: 879-903.
11. Levine M, Chang T. Therapeutic drug monitoring of phenytoin: rationale and current status. Clin Pharmacokinet 1990;19:341-58.
12. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part II). Clin Pharmacokinet 1990;18: 131-50.
13. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part I). Clin Pharmacokinet 1990;18:37-60.
14. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: cosegregation of oxidative o-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
15. Franc JE, Duncan GF, Farmen RH, Pittman KA. High performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr B Biomed Appl 1986;382:199-205.
16. Sawchuck RJ, Cartier LL. Liquid chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenyl hydantoin in plasma and urine. Clin Chem 1980; 26:535-9.
17. Riegelman S, Collier P. An application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
18. Gill JL. Design and analysis of experiments in the animal and medical sciences. Ames, IA: Iowa State University Press, 1978:178-82.
19. Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984;12:649-55.
20. Kut H. Phenytoin interactions with other drugs: clinical aspects. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Lippincott-Raven Publishers, 1995: 315-28.
21. Altshuler LA. Depression and epilepsy. In: Theodore WH, Devinsky O, eds. Epilepsy and behavior. New York: Wiley-Liss, 1991:47-65.
22. Edwards JG. Antidepressants and seizures: epidemiological and clinical aspects. In: Trimble MR, ed. The psychopharmacology of epilepsy. Chichester, England: John Wiley, 1985:119-39.
23. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports [correspondence]. J Neurol Neurosurg Psychiatry 1992;55:412-3.
24. Darley J. Interaction between phenytoin and fluoxetine. Seizure 1994;3/2:151-2.
25. Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine [letter]. N Z Med J 1994;107:19.
26. Nightingale S. Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers [letter]. JAMA 1994;271:1067.
27. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36[suppl 5]:S8-13.
28. Levy RH, Trager WF, Kunze KL, Thummel K, Wienkers L, Bishop F, Bajpai M, Mather GG. Prediction of phenytoin interactions based on cytochrome P450 isoforms [abstract]. Epilepsia 1994; 35[suppl 8]:143.
29. Andersen BB, Mikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, Lund J, Mengel H. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991;10:201-4.
30. Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985;7:283-9.